ASTRAZENECA PLC
ASTRAZENECA PLC (AZN): 351 pipeline candidates · 142 upcoming catalysts · 511 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
N/A
D/E 1.34 · 0% dilution
Lead: Phase 3
351 candidates
142 upcoming, next in ~1d
0 buys · 1 sell (180d)
A transparent, data-derived signal for ASTRAZENECA PLCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$72.8B
Cash
$1.3B
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (351 candidates)
| Drug | Phase |
|---|---|
| (osimertinib cohort | Phase 3 |
| [111in]-fpi-2107 | Phase 1 |
| [11C]AZ14132516 | Phase 1 |
| [11C]AZ1419 3391 | Phase 1/Phase 2 |
| [14c]azd0780 | Phase 3 |
| [14c]azd0780 solution for infusion | Phase 3 |
| [14c]azd4144 | Phase 2 |
| [14c]azd4144 solution for infusion | Phase 2 |
| [14c]azd5004 | Phase 1 |
| [14c]azd5004 solution for infusion | Phase 1 |
Showing 10 of 351 candidates. Sign up for full pipeline.
Upcoming Catalysts (142)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,315
Total value held
$140.68B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 90,080,284 | $17.61B |
| investor ab | 51,587,810 | $10.17B |
| fmr llc | 29,601,724 | $5.80B |
| legal & general group plc | 25,849,978 | $5.01B |
| janus henderson group plc | 23,898,848 | $4.64B |
| wellington management group llp | 23,751,085 | $4.63B |
| bank of america corp /de/ | 19,058,327 | $3.76B |
| vanguard asset management, ltd | 18,535,315 | $3.62B |
| primecap management co/ca/ | 18,213,708 | $3.59B |
| franklin resources inc | 17,792,161 | $3.49B |
Showing top 10 of 1,315 institutional holders of ASTRAZENECA PLC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ASTRAZENECA PLC's pipeline?
ASTRAZENECA PLC (AZN) has 351 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ASTRAZENECA PLC's lead drug candidate?
ASTRAZENECA PLC's most advanced tracked candidate is (osimertinib cohort (Phase 3) for Carcinoma, Non-Small-Cell Lung.
What is ASTRAZENECA PLC's next catalyst?
ASTRAZENECA PLC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Inves" — expected June 19, 2026.
What is ASTRAZENECA PLC's market capitalization?
ASTRAZENECA PLC's market capitalization is approximately $72.8B.
Who is the CEO of ASTRAZENECA PLC?
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. is the chief executive officer of ASTRAZENECA PLC (AZN).
Get the full picture on ASTRAZENECA PLC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.